McAdam LLC’s Cognition Therapeutics CGTX Stock Holding History

McAdam LLC’s Portfolio CGTX Stock Details CGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$56.6K	Sell	59,004 -5,549	-9%	-$5.58K	﹤0.01%	523
2026 Q2	$74.2K	Sell	64,553 -5,400	-8%	-$6.39K	﹤0.01%	505
2026 Q1	$53.1K	Sell	69,953 -4,156	-6%	-$4.84K	﹤0.01%	438
2025 Q4	$100K	Buy	74,109 +2,034	+3%	+$3.3K	﹤0.01%	411
2025 Q3	$97.3K	Buy	+72,075	New	+$98.3K	﹤0.01%	389

Other funds holding CGTX

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

Bangor Savings Bank Bangor, Maine $1.31B AUM 12.25% 1-Year Est. Return

CWA Asset Management Group Naples, Florida $3.39B AUM 25.16% 1-Year Est. Return

Barry Investment Advisors New Bedford, Massachusetts $524M AUM 15.38% 1-Year Est. Return

RPGK

Retirement Planning Group (Kansas) Leawood, Kansas $4.01B AUM 11.74% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

McAdam LLC's CGTX Position: Q3 2026 in Review

McAdam LLC reduced its Cognition Therapeutics (CGTX) stake by 8.6% in Q3 2026, selling an estimated $5.58K and leaving 59,004 shares worth $56.6K. The position accounts for ﹤0.01% of the portfolio, ranked #523.

McAdam LLC first reported a position in CGTX in Q3 2025 and has held it in 5 quarters since. The position peaked at $100K in Q4 2025. 9 funds tracked by Wall St. Rank hold CGTX as of Q3 2026.

McAdam LLC held 59,004 shares of Cognition Therapeutics worth $56.6K as of Q3 2026.
McAdam LLC sold 5,549 Cognition Therapeutics shares in Q3 2026, an estimated $5.58K.
Cognition Therapeutics made up ﹤0.01% of McAdam LLC's portfolio in Q3 2026, its #523 holding.
McAdam LLC first reported a position in Cognition Therapeutics in Q3 2025 and has held it in 5 quarters since.
McAdam LLC's Cognition Therapeutics position peaked at $100K in Q4 2025.
9 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2026.

Based on McAdam LLC's 13F filing for Q3 2026, filed 21 Oct 2026.